ARS Pharmaceuticals Inc(SPRY) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -2.17 | Insider Own | 34.38% | Shs Outstand | 99.4M | Perf Week | -15.28% |
| Market Cap | 0.36B | Forward P/E | - | EPS next Y | 54.34% | Insider Trans | -0.08% | Shs Float | 65.3M | Perf Month | -15.08% |
| Enterprise Value | 0.32B | PEG | - | EPS next Q | -0.3 | Inst Own | 71.58% | Short Float | 30.38% | Perf Quarter | -28.65% |
| Income | -0.22B | P/S | 3.11 | EPS this Y | -2.59% | Inst Trans | -4.67% | Short Ratio | 11.51 | Perf Half Y | -55.69% |
| Sales | 0.12B | P/B | 29.09 | EPS next 5Y | 88.35% | ROA | -76.53% | Short Interest | 19.82M | Perf YTD | -68.58% |
| Book/sh | 0.13 | P/C | 2.53 | EPS past 3/5Y | -26.04% -12.85% | ROE | -210.35% | 52W High | -72.17% ($13.15) | Perf Year | -59.24% |
| Cash/sh | 1.45 | P/FCF | - | Sales past 3/5Y | 300.09% - | ROIC | -197.3% | 52W Low | 3.83% ($3.53) | Perf 3Y | 5.48% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -343.67% | Gross Margin | 71.37% | Volatility(W/M) | 6.78% 6.52% | Perf 5Y | -57.59% |
| Dividend TTM | - | EV/Sales | 2.71 | Sales Y/Y TTM | 4.08% | Oper. Margin | -184.96% | ATR (14) | 0.26 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 3.28 | EPS Q/Q | -37.56% | Profit Margin | -184.24% | RSI (14) | 34.54 | Recom | 1 |
| Dividend Gr. 3/5Y | - | Current Ratio | 3.48 | Sales Q/Q | 114.15% | SMA20 | -10.8% ($4.1) | Beta | 0.93 | Target Price | $24.33 |
| Payout | - | Debt/Eq | 7.73 | Earnings | 2026/11/5 | SMA50 | -20.71% ($4.62) | Rel Volume | 1.19 | Prev Close | $3.65 |
| Employees | 163 | LT Debt/Eq | 7.73 | EPS/Sales Surpr. | -31.88% 7.46% | SMA200 | -50.77% ($7.43) | Avg Volume(3M) | 1.72M | Price | $3.66 |
| IPO | 2020/12/4 | Option/Short | Yes/Yes | Trades | 9611 | Volume | 2,042,657 | Change | 0.27% |
💧 ARS Pharmaceuticals (SPRY) is a U.S. biotech company that develops and commercializes "neffy," a needle-free, nasal-spray epinephrine product. It is a non-injectable treatment designed to replace traditional injectable auto-injectors used for Type I allergic reactions such as anaphylaxis, and it holds the distinction of being the first non-injectable epinephrine product approved in the United States.
Over the past 1 year, on the lower side
72% below its 1-year high.
Traded about as much as usual. That is 119% of its average volume.
Next earnings report: November 5
6 days to go.
SPRY has weak earnings and a weak balance sheet
Losses exceed revenue. The business is barely earning yet.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by -2.6% this year.
Tap to view numbers
Relative to sales, it looks cheap
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $311. Peers typically go for $1,217.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -57.6%. The S&P 500 did +68% over the same period.
Tap to view numbers
No dividend
There is no profit to distribute yet.
Short interest is a burden
30.4% of the float is sold short.
Tap to view numbers
Multiple ETFs hold this stock, but only a sliver
Buying this ETF gives you exposure to this stock as well.
It ranks #249 of 594 in the industry
Based on market cap of $364M.
ZURA#246 Zura Bio Ltd $371M PER - 
RLMD#247 Relmada Therapeutics Inc $367M PER - 
OBIO#248 Orchestra BioMed Holdings Inc $366M PER - SPRY#249 ARS Pharmaceuticals Inc $364M PER - 
KYTX#250 Kyverna Therapeutics Inc $362M PER - 
FAQ
What kind of company is SPRY?
SPRY belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of SPRY?
The market cap of SPRY is approximately $364M, ranking 3,449 within its sector.
What is the 52-week high and low for SPRY?
SPRY has recorded a 52-week high of $13.15 and a low of $3.53.
